मिसिल स.- 8(149)/2026/डी.पी/एनपीपीए-डीवी-II

F. No. 8(149)/2026/DP/NPPA-Div. II

कार्यवाही स. : 281/149/2026/F

Proceeding No: 281/149/2026/F

Minutes of the 281st (overall) and 149th meeting of the Authority under DPCO, 2013 held on 30.07.2026 at 12:30 PM.

The 281st meeting of the Authority (overall), which is the 149th meeting under the DPCO, 2013 was held on 30.07.2026 at 12:30 PM under the Chairmanship of Shri P. Krishnamurthy, Chairman, NPPA. The following Authority members were present during the meeting:

(i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
(ii) Shri Anand Kumar Pal, Chief Adviser (Cost), O/o Chief Adviser Cost, Department of Expenditure
(iii) Dr. Rose Mary K. Abraham, Economic Advisor, Department of Economic Affairs

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

(i) Shri Rajiv Wadhawan, Adviser (Cost)
(ii) Ms. Priyanka Sachdeva, Joint Director (Pricing)
(iii) Shri Bhiva Ram Yadav, Assistant Director (Pricing)
(iv) Shri Mayur Panwar, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of minutes of 148th Meeting held on 07.07.2026.

1.1 The Authority confirmed the minutes of the meeting without any change.

2. Agenda item no. 2 – Action Taken Report (ATR) on decisions taken by NPPA in its 148th Meeting held on 07.07.2026.

2.1 Noted.

3. Agenda item no. 3 – Status of new drug application.

3.1 Noted.

4. Agenda item no. 4 – New Drug application for price fixation under Paragraph 5 and 15 of DPCO, 2013.

4.1 The Authority deliberated on 23 (Twenty-Three) cases of retail price fixation of new drugs as presented in Agenda no. 4(1) to 4(23) falling under the purview of paragraph 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 23 (Twenty-Three) new drugs under paragraph 5 and 15 of DPCO, 2013 as given in **Table 1 below:**

Table No. 1: Retail price fixation of new drugs

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (₹)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	4(1)(a) & 4(1)(b)	Atorvastatin, Clopidogrel and Aspirin Capsules	Each Hard Gelatin Capsule Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 10 mg (As Film Coated Atorvastatin Tablets IP), Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (As Film Coated Clopidogrel Tablets IP), Aspirin IP 75 mg (As Aspirin Gastro-Resistant Tablets IP)	1 Capsule	(i) M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharma Laboratories Ltd.; (ii) M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharmaceutical Industries Ltd.	6.37
2	4(2)(a) & 4(2)(b)	Atorvastatin, Clopidogrel and Aspirin Capsules	Each Hard Gelatin Capsule Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 20 mg (As Film Coated Atorvastatin Tablets IP, Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (As Film Coated Clopidogrel Tablets IP) Aspirin IP 75 mg (As Aspirin Gastro-Resistant Tablets IP)	1 Capsule	(i) M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharma Laboratories Ltd.; (ii) M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharmaceutical Industries Ltd.	8.89
3	4(3)	Clonazepam and Paroxetine Controlled Release Tablets	Each Film Coated Bilayered Tablet Contains: Clonazepam IP 0.5 mg, Paroxetine Hydrochloride Hemihydrate IP eq. to Paroxetine 12.5 mg (As Controlled Release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mankind Pharma Ltd.	17.52
4	4(4)	Clonazepam and Paroxetine Controlled Release Tablets	Each Film Coated Bilayered Tablet Contains: Clonazepam IP 0.5 mg, Paroxetine Hydrochloride Hemihydrate IP eq. to Paroxetine 25 mg (As Controlled Release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mankind Pharma Ltd.	20.06
5	4(5)	Desvenlafaxine Extended Release and Clonazepam Tablets	Each Uncoated Bilayered Tablet Contains: Desvenlafaxine Succinate USP Eq. to Desvenlafaxine 50 mg (In Extended Release Form), Clonazepam IP 0.5 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Mankind Pharma Ltd	17.47
6	4(6)	Desvenlafaxine Extended Release and Clonazepam Tablets	Each Uncoated Bilayered Tablet Contains: Desvenlafaxine Succinate USP Eq. to Desvenlafaxine 100mg (In Extended-Release Form), Clonazepam IP 0.5 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Mankind Pharma Ltd	25.83
7	4(7)	Escitalopram Oxalate and Clonazepam Tablets	Each film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 5 mg, Clonazepam IP 0.5 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Ipca Laboratories Ltd.	10.72
8	4(8)	Etoricoxib and Paracetamol Tablets	Each Film Coated Tablet contains: Etoricoxib IP 60 mg, Paracetamol IP 325 mg	1 Tablet	M/s JK Print Pack (Pharma Division)/ M/s Torrent Pharmaceuticals Ltd	10.90
9	4(9)	Ferrous Ascorbate and Folic Acid Tablets	Each film coated tablet contains: Ferrous Ascorbate IP eq. to Elemental Iron 100 mg, Folic Acid IP 1.5 mg	1 Tablet	M/s Crius Life sciences Pvt. Ltd./ M/s Eris Lifesciences Ltd.	16.92
10	4(10)	Iron and Folic Acid Syrup	Each 15 ml contains: Iron (III) Hydroxide Polymaltose	1 ML	M/s Skymap Pharmaceuticals Pvt.	0.28

			complex eq. to Elemental Iron 50 mg, Folic Acid IP 0.5 mg		Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	
11	4(11)	Myo-Inositol, D-Chiro Inositol and Vitamin D3 Powder	Each 5g Sachet contains: Vitamin D3 (Stabilized form) 1000 IU, Myo-Inositol IP 2000 mg, D-Chiro Inositol 50 mg	1 GM	M/s Safetab Life Science/ M/s Anax Lifescience Pvt. Ltd	9.29
12	4(12)	Ofloxacin and Metronidazole Suspension	Each 5 ml contains: Ofloxacin IP 100 mg, Metronidazole Benzoate IP eq. to Metronidazole 200 mg	1 ML	M/s Hema Laboratories Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	1.09
13	4(13)	Ofloxacin and Metronidazole Suspension	Each 5 ml contains: Ofloxacin IP 50 mg, Metronidazole Benzoate IP eq. to Metronidazole 100 mg	1 ML	M/s Hema Laboratories Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	0.86
14	4(14)	Paracetamol Oral Suspension	Each 5 ml contains: Paracetamol IP 500 mg	1 ML	M/s Naxpar Pharma Pvt. Ltd. / M/s Glaxosmithkline Pharmaceuticals Ltd.	0.66 **(Note-1)**
15	4(15)	Telmisartan and Metoprolol Succinate (ER) Tablets	Each film coated bilayered Tablet contains: Telmisartan IP 40 mg, Metoprolol Succinate IP eq. to Metoprolol Tartrate 25mg (as Extended release)	1 Tablet	M/s Windlas Biotech Ltd/ M/s FDC Ltd	15.01
16	4(16)	Telmisartan and Metoprolol Succinate (ER) Tablets	Each film coated bilayered Tablet contains: Telmisartan IP 40 mg, Metoprolol Succinate IP eq. to Metoprolol Tartrate 50 mg (as Extended release)	1 Tablet	M/s Windlas Biotech Ltd/ M/s FDC Ltd	18.50 **(Note-2)**
17	4(17)	Telmisartan, Chlorthalidone and Metoprolol Succinate (ER)Tablets	Each film coated bilayer tablet contains: Telmisartan IP 40 mg , Chlorthalidone IP 6.25 mg, Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate 50 mg (As extended-release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Mankind Pharma Ltd	11.77
18	4(18)	Telmisartan, Chlorthalidone and Metoprolol Succinate (ER)Tablets	Each film coated bilayer tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 6.25 mg, Metoprolol Succinate IP 23.75 mg eq. to Metoprolol Tartrate 25 mg (As extended-release form)	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Mankind Pharma Ltd	11.67
19	4(19)	Nebivolol Hydrochloride and Telmisartan Tablets	Each uncoated bilayered tablet contains: Nebivolol Hydrochloride IP Eq. to Nebivolol 2.5 mg, Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Torrent Pharmaceuticals Ltd.	13.70
20	4(20)(a), 4(20)(b) & 4(20)(c)	Sitagliptin, Glimepiride and Metformin Hydrochloride Extended-Release Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg, Glimepiride IP 2mg, Metformin Hydrochloride (As Extended Release) IP 1000 mg	1 Tablet	(i) M/s Exemed Pharmaceuticals/ M/s Alkem Laboratories Ltd.; (ii) M/s Exemed Pharmaceuticals/ M/s Sun Pharma Laboratories Ltd. ; (iii) M/s Exemed Pharmaceuticals/	19.46

					M/s Torrent Pharmaceuticals Ltd.	
21	4(21)(a), 4(21)(b) & 4(21)(c)	Sitagliptin, Glimepiride and Metformin Hydrochloride Extended-Release Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg, Glimepiride IP 1 mg, Metformin Hydrochloride (As Extended Release) IP 1000 mg	1 Tablet	(i) M/s Exemed Pharmaceuticals/ M/s Alkem Laboratories Ltd.; (ii) M/s Exemed Pharmaceuticals/ M/s Sun Pharma Laboratories Ltd. ; (iii) M/s Exemed Pharmaceuticals/ M/s Torrent Pharmaceuticals Ltd.	17.73
22	4(22)	Combikit of Clarithromycin Tablets IP, Pantoprazole Tablets IP and Amoxicillin Tablets USP	Each Strip Contains: A. Clarithromycin Tablets IP (2 Tablets) Each Film Coated Tablet Contains: Clarithromycin IP 500 mg, B. Pantoprazole Tablets IP (2 Tablets) Each Enteric Coated Tablet Contains: Pantoprazole Sodium IP eq. to Pantoprazole 40 mg, C. Amoxicillin Tablets USP (2 Tablets) Each Film Coated Tablet Contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 1000 mg	1 Strip	M/s Malik Lifesciences Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.	122.56
23	4(23)	Dapagliflozin, Pioglitazone and Metformin Hydrochloride SR Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10mg, Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg, Metformin Hydrochloride IP (as sustained release) 1000mg	1 Tablet	M/s Eris Lifesciences Ltd.	18.77

Note-1: *The Authority noted the representation received from the applicant company for correction in the PTR of one of the line items considered in the uploaded draft worksheet. However, the same was not considered as the Pharmatrac has re-confirmed the same PTR as reported earlier. Hence, the Authority decided that no change is required in the draft worksheet uploaded.*

Note-2: *The Authority observed that one of the line items i.e. 'MET XL T 40/50 MG TABLET 15' is discontinued in Jan-22 and therefore, the same be removed from the calculation of retail price. Accordingly, the retail price was revised to ₹18.50/- from ₹18.66/-.*

5. Agenda item no. 5: Minutes of 78th meeting of the Multidisciplinary Committee of Experts held on 24.06.2026.

5.1 Noted.

6. Agenda item no. 6: Retail price fixation of Each vial contains: Paclitaxel IP 100 mg for M/s. Intas Pharmaceuticals Ltd. under DPCO, 2013

6.1 The Authority took note of the Form-I application submitted by M/s Intas Pharmaceuticals Ltd., the subsequent request of the company for withdrawal of the application,

the clarification furnished by the Office of the DCGI, the recommendations of the 78th Multidisciplinary Committee (MDC), the representation dated 06.07.2026 submitted by the company against the recommendations of the MDC.

6.2 The Authority observed that the MDC has comprehensively examined the matter after considering the relevant provisions of the Drugs (Prices Control) Order, 2013, the National List of Essential Medicines (NLEM), 2022, the clarification received from the Office of the DCGI, and the submissions made by the company. The Authority further noted that the MDC has concluded that injectable dosage forms include conventional injections as well as delivery systems such as lipid/liposomal formulations and that separate prices are to be fixed only where such formulations are specifically mentioned in Schedule I. Since Paclitaxel lipid formulation is not separately specified in Schedule I, the MDC has recommended that the company comply with the ceiling price notified for Paclitaxel Injection.

6.3 The Authority deliberated on the representation submitted by the company and observed that the issues raised therein have already been taken into consideration by MDC in its 78th meeting and that no new facts have been presented in the said representation that merit re-consideration of the matter.

6.4 Accordingly, after detailed deliberations, the Authority approved the recommendations of the Multidisciplinary Committee without any change and decided that the formulation under discussion is a scheduled formulation for which ceiling prices have already been notified.

7. Agenda item no. 7: Ceiling price fixation of IV Fluids formulations under NLEM, 2022

7.1 The Authority took note of the historical background relating to fixation of ceiling prices of IV Fluids, the evolution of the pricing methodology under the Drugs (Prices Control) Order, 2013, the various review orders issued by the Department of Pharmaceuticals, the recommendations of the earlier Committee of Experts and the Multi-Disciplinary Committee (MDC), as well as the existing methodology being followed for fixation of prices of IV Fluids in normal packs and packs having special features.

7.2 The Authority recalled that the matter had earlier been deliberated in its 146th meeting dated 26.05.2026 wherein it was decided *to refer the matter to the Multi-Disciplinary Committee (MDC) for further examination regarding methodology for ceiling prices fixation of IV Fluids including packs with special features*.

7.3 The Authority was informed that the matter was placed in 78th meeting of MDC held on 24.06.2026. The Authority noted the observations of MDC that although a substantial price difference exists between non-glass packs and non-glass packs with special features for certain IV Fluids, the difference on account of special features represents only a minor innovation in packaging. Further, all IV Fluids are similar in nature and only the composition varies while the container remains substantially the same. The Authority noted that in respect of the following 8 IV fluid formulations for packages in non-glass with special features i.e.

Sl. No.	Medicines	Dosage form and Strength
(1)	(2)	(3)
1.	Glucose	Injection 5% 1000ml
2.	Glucose	Injection 5% 500ml

3.	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B) 1000ml
4.	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B) 500ml
5.	Sodium Chloride	Injection 0.9% 100ml
6.	Sodium Chloride	Injection 0.9% 250ml
7.	Sodium Chloride	Injection 0.9% 500ml
8.	Sodium Chloride	Injection 0.9% 1000ml

the ceiling prices were fixed based on pack-size, packing material and special features for IV fluids (non-PVC) on the basis of market data of September 2013 vide S.O. 1993(E) dated 03.06.2016 and subsequently, annual WPI revision is being carried out.

7.4 However, on the other hand, the ceiling price of following 10 IV fluid formulations for packages in non-glass with special features i.e.

Sl No	**Medicines**	**Dosage form and Strength**
(1)	**(2)**	**(3)**
1.	Ringer lactate	Injection 100 ml
2.	Ringer lactate	Injection 250 ml
3.	Ringer lactate	Injection 500 ml
4.	Ringer lactate	Injection 1000 ml
5.	Metronidazole	Injection (0.5%w/v) /500mg/100ml in 100ml pack
6.	Mannitol	Injection 20% in 100 ml pack
7.	Mannitol	Injection 20% in 350 ml pack
8.	Dextrose (Glucose)	Injection (25% w/v) in 100 ml pack
9.	Dextrose (Glucose)	Injection (25% w/v) in 500 ml pack
10.	Ciprofloxacin	Injection 200mg/100ml in 100 ml pack

are being fixed by allowing an additional 15% over the notified ceiling price of the formulation packages without special features.

7.5 The Authority noted that over a period of time, two separate methodologies have developed for fixation of separate ceiling prices of IV Fluid formulation packages in non-glass with special features. Hence, there is a need to rationalize the methodology being followed so that ceiling prices of entire spectrum of IV fluids follow the same principle. The Authority agreed with the observations of the MDC that a uniform methodology for fixation of ceiling prices of all IV Fluids with special features under NLEM, 2022 is necessary to ensure consistency across formulations of similar nature and that the existing methodology of allowing an additional 15% over the notified ceiling price for formulations with special features provides an appropriate and rational framework.

7.6 The Authority was apprised of two representations received on the recommendation of MDC requesting for continuation of the separate pricing mechanism for special feature products and did not find any merit in the representation.

7.7 Accordingly, the Authority agreed with the recommendations of the Multi-Disciplinary Committee and approved the methodology of allowing an additional 15% over the notified ceiling price while fixing the ceiling prices of all IV Fluids with special features under NLEM, 2022 (including Glucose 5%, Sodium Chloride 0.9% and Glucose 5% + Sodium Chloride

0.9%). The Authority directed that necessary action be taken for fixation of ceiling prices of the concerned IV Fluids in accordance with the approved methodology.

8. Agenda item no. 8: Status of implementation of Review cases

8.1 Noted.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.

SAI AHLLADINI PANDA

Digitally signed by SAI AHLLADINI PANDA
Date: 2026.07.31 17:52:22 +05'30'

(Sai Ahlladini Panda)
Member Secretary